Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients
Objective: To describe the treatment outcomes of patients receiving dolutegravir (DTG) in a ‘real-world setting’ in Belgium. Design: Retrospective, observational, multicenter cohort. Methods: Inclusion criteria: HIV-1 patients at least 18 years old having received DTG as part of their combined antiretroviral therapy (cART) between 1 April 2014 and 1 December 2017. Primary endpoint: rate of virologic suppression, defined as plasma HIV-1 viral load less than 50 copies/ml, at weeks 24, 48, and 96. Secondary endpoints: durability, expressed as probability of experiencing loss of virologic suppress... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2020 |
Reihe/Periodikum: | AIDS ; volume 34, issue 8, page 1151-1159 ; ISSN 0269-9370 1473-5571 |
Verlag/Hrsg.: |
Ovid Technologies (Wolters Kluwer Health)
|
Schlagwörter: | Infectious Diseases / Immunology / Immunology and Allergy |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26507215 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://dx.doi.org/10.1097/qad.0000000000002533 |